Search Within

Michael Andrew Postow

  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (20)
  2. Meeting Abstract (11)
  3. Guidelines (1)
  4. Research Letter (1)
Groups
  1. Department of Medicine (33)
  2. Gastrointestinal Oncology Service (33)
  3. Melanoma Disease Management Team (33)
  4. Melanoma and Immunotherapeutics Service (33)
  5. Solid Tumor Oncology Division (33)
  6. GSK Faculty (28)

More Groups

People
  1. Jedd Wolchok (23)
  2. Margaret Callahan (16)
  3. James Harding (14)
  4. Neil Segal (11)
  5. Alexander Lesokhin (10)
  6. Matthew Hellmann (8)

More People

Years
  1. 2025 (2)
  2. 2024 (1)
  3. 2023 (1)
  4. 2022 (2)
  5. 2021 (1)
  6. 2020 (1)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. European Journal of Cancer (2)
  3. Journal of Nuclear Medicine (2)
  4. Pigment Cell & Melanoma Research (2)
  5. The Oncologist (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. Oxford University Press (4)
  3. Wiley Blackwell (3)
  4. American Association for Cancer Research (2)
  5. Cell Press (2)
  6. Elsevier Inc. (2)

More Publishers

Results (33)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
    Journal Article

    Belum, V. R.; Benhuri, B.; Postow, M. A.; Hellmann, M. D.; Lesokhin, A. M.; Segal, N. H.; Motzer, R. J.; Wu, S.; Busam, K. J.; Wolchok, J. D.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Pneumonitis with anti-PD-1/PD-L1 therapy
    Meeting Abstract

    Naidoo, J.; Cunningham, J.; Woo, K. M.; Hellmann, M. D.; Postow, M. A.; Drilon, A. E.; Chaft, J. E.; Lesokhin, A. M.; Segal, N. H.; Callahan, M. K.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Meeting Abstract

    Wolchok, J. D.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Reed, K.; Burke, M. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience
    Journal Article

    Luke, J. J.; Callahan, M. K.; Postow, M. A.; Romano, E.; Ramaiya, N.; Bluth, M.; Giobbie-Hurder, A.; Lawrence, D. P.; Ibrahim, N.; Ott, P. A.; more...
    Cancer (2013)

    Fulltext@MSK | Save
  • Nivolumab plus Ipilimumab in advanced melanoma
    Journal Article

    Wolchok, J. D.; Kluger, H.; Callahan, M. K.; Postow, M. A.; Rizvi, N. A.; Lesokhin, A. M.; Segal, N. H.; Ariyan, C. E.; Gordon, R. A.; Reed, K.; more...
    New England Journal of Medicine (2013)

    Fulltext@MSK | Save
  • Ipilimumab for patients with advanced mucosal melanoma
    Journal Article

    Postow, M. A.; Luke, J. J.; Bluth, M. J.; Ramaiya, N.; Panageas, K. S.; Lawrence, D. P.; Ibrahim, N.; Flaherty, K. T.; Sullivan, R. J.; Ott, P. A.; more...
    The Oncologist (2013)

    Fulltext@MSK | Save
  • Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg)
    Meeting Abstract

    Postow, M. A.; Yuan, J.; Panageas, K.; Bogatch, K.; Callahan, M.; Cheng, M.; Schroeder, S. E. A.; Kendle, R. F.; Harding, J. J.; Dickson, M. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Hypersensitivity skin reactions in melanoma patients treated with vemurafenib after ipilimumab therapy
    Meeting Abstract

    Harding, J. J.; Lacouture, M. E.; Pulitzer, M.; Callahan, M.; Postow, M. A.; Carvajal, R. D.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save